In the News

May 05, 2025

Fierce Biotech

Immutep takes immunotherapy a step further with ‘impressive’ survival data from Keytruda combo

May 05, 2025

OncLive

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1 Negative HNSCC

Dec 13, 2024

EurekAlert | AAAS

Unlocking the potential to better target cancer with immunotherapy

Nov 14, 2024

OncLive

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC

Sep 23, 2024

Finance News Network

Immutep announces positive results in head and neck cancer treatment

Media

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 – Executive Director and CEO Marc Voigt discusses encouraging results in second-line non-small cell lung cancer.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 28 Mar 2022 – Executive Director and CEO, Marc Voigt speaks to Naureen Quibria, PhD. of Maxim Group about LAG-3 and an overview of the company outlining future plans

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the TACTI-002 and TACTI-003 trials – Eftilagimod alpha for metastatic head and neck squamous cell carcinoma

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the final results from the Phase IIb AIPAC trial of eftilagimod alpha vs placebo with chemo for HR+ HER2- MBC

Marc Voigt, Chief Executive Officer of Immutep (ASX:IMM; NASDAQ: IMMP) presents at the Bell Potter Healthcare Conference 2021

Listen to the Spotify Podcast Interview of Dr. Frederic Triebel by Neil Canavan “Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage “